<DOC>
	<DOCNO>NCT02378415</DOCNO>
	<brief_summary>The objective double-blinded placebo-controlled pilot study determine whether single sub-anesthetic rapid IV bolus dose ketamine administer acutely depressed patient without suicidality significant rapid antidepressant effect acutely depressed population . The study pursue primary outcome measure whether significant reduction depressive symptom , assess BSS BHS , occur shortly administration ketamine 40 , 80 , 120 , 240 minute . A secondary outcome measure assess determine whether single infusion ketamine sustain reduction depressive symptom within 2-weeks post-infusion reduction BDI score . Suicidal ideation also assess determination reduction sustain reduction post infusion assessment Beck Suicidal Ideation Scale ( BSS ) , Beck Hopelessness Scale ( BHS ) Beck Depression Inventory ( BDI ) similar interval .</brief_summary>
	<brief_title>Subanesthetic IV Bolus Ketamine Treatment Acute Depression</brief_title>
	<detailed_description>A determination hospital admittance consult psychiatrist make prior study participation . Only person admit psychiatric ward eligible enroll study . After consent participate trial meeting inclusion criterion study ( include baseline BDI , BSS , BHS ) , voluntarily present acutely depressed patient , without suicidal ideation , randomize two group administer standard care treatment intravenous ketamine ( 0.2mg/kg 1-2 minute ) standard care treatment intravenous normal saline ( equal volume ketamine dose ) . All prepared study solution mix administer ED staff and/or nursing staff per exist NMCSD ED protocol . All subject blind treatment give , either IV bolus dose ketamine 0.2-mg/kg 1-2 minute placebo solution compose equal IV bolus dose ( overall volume ) 0.9 normal saline solution administer . Thereafter , patient evaluate clinically BSS , BHS , BDI 40 , 80 , 120 , 240 minute . All study participant monitor medically ED least full 240-minute protocol declare medically clear , accordance standard care practice ED provider , transfer inpatient psychiatric ward monitoring least 24-hours prior discharge hospital . All enrol patient administer another BSS , BHS , BDI prior discharge hospital . The length hospital stay also record analysis , consider secondary outcome measure study . Psychiatric determination discharge hospital base clinical assessment , presentation history , hospital course consider outcome measure study . All patient include study re-assessed within 2 week another BSS , BHS , BDI determination sustainability effect . Appropriate follow-up care psychiatrist afford study participant discharge hospital . Additionally , severe adverse side effect develop ; treatment administer enrolled patient may un-blinded third-party shift medical monitor ( i.e . Charge Nurse ) request emergency room provider . Additionally , give potential psychotropic effect ketamine assure patient sufficiently monitor appropriately medically clear , participant study require remain clinical observation emergency room prior transfer psychiatric ward , least , full 4-hour treatment cycle longer clinically indicate . All participant study allow enroll study undergo protocol 's treatment .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Ketamine</mesh_term>
	<criteria>1 . BSS great 4 2 . BHS great 8 3 . BDI great 19 4 . Ability give inform consent . 5 . Active Duty military status . 6 . Verified negative qualitative pregnancy test . 7 . All participant must accept psychiatric admission hospital PRIOR consideration enrollment study . 1 . Psychosis Bipolar Disorder . 2 . Pregnancy 3 . Involuntary Status presentation ED . 4 . UDS positive illicit drug abuse . 5 . Blood Alcohol level great zero . 6 . Previous enrollee treatment protocol exclude repeat participation . 7 . Any patient brought command direct psychiatric evaluation . 8 . Specific contraindication use ketamine follow circumstance condition , personnel follow excluded participation study : 1 . Patients elevate intracranial pressure , uncontrolled hypertension , coronary artery disease , aneurysms , thyrotoxicosis , CHF , recent history head eye injury , angina . 2 . All personnel significant elevation blood pressure would constitute serious hazard overall health wellbeing . 3 . Patients currently utilize follow medication : conivaptan , Disatinib , peginterferon alfa2b , quazepam , tocilizumab</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Depression</keyword>
</DOC>